<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="2666">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on October 07, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04335162</url>
  </required_header>
  <id_info>
    <org_study_id>20reamedcovid01</org_study_id>
    <nct_id>NCT04335162</nct_id>
  </id_info>
  <brief_title>Cardiovascular Complications and COVID-19 (CovCardioVasc)</brief_title>
  <acronym>CovCardioVasc</acronym>
  <official_title>Screening of Cardiovascular Complications in Patients With COVID-19</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Universitaire de Nice</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Hospitalier Universitaire de Nice</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Patients with COVID-19 in the Intensive Care Unit (ICU) or hospitalized with severe form have
      a poor prognosis (almost 30% rate of death). They present often a high cardiovascular risk
      profile (almost 30% of hypertension and 19% of diabetes). Troponin has been described to be
      elevated in a high proportion of patients (one fifth of all patients and 50% of
      non-survivors) suggesting the possibility of cardiomyopathies. High levels of DDimers (81% of
      non survivors) and fibrin degradation products are also associated with increased risk of
      mortality suggesting also the possibility of venous thromboembolism. Therefore, screening for
      cardiomyopathies and venous thromboembolism could represent an important challenge for
      patients with COVID-19 management.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 28, 2020</start_date>
  <completion_date type="Anticipated">August 28, 2020</completion_date>
  <primary_completion_date type="Anticipated">August 28, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Determine the incidence of cardiomyopathies and venous thromboembolism</measure>
    <time_frame>28 days</time_frame>
    <description>Incidence of cardiomyopathies and/or venous thromboembolism at day 28</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mortality</measure>
    <time_frame>28 days</time_frame>
    <description>Incidence of mortality at day 28</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of mechanical ventilation</measure>
    <time_frame>28 days</time_frame>
    <description>Number of day of using mechanical ventilation for each patients</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>shock at day 28</measure>
    <time_frame>28 days</time_frame>
    <description>Incidence of shock at day 28</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>length of stay in the intensive care unit</measure>
    <time_frame>28 days</time_frame>
    <description>Number of day in intensive care unit</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">100</enrollment>
  <condition>COVID</condition>
  <condition>Acute Coronary Syndrome</condition>
  <condition>Myocardial Infarction</condition>
  <condition>Myocarditis</condition>
  <condition>Venous Thromboembolism</condition>
  <condition>Deep Vein Thrombosis</condition>
  <condition>Pulmonary Embolism</condition>
  <arm_group>
    <arm_group_label>Intensive care unit patients</arm_group_label>
    <description>Patients with COVID-19 hospitalized in an intensive care unit</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Non intensive care unit patients</arm_group_label>
    <description>Patients with COVID-19 hospitalized who are not in an intensive care unit</description>
  </arm_group>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      whole blood
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Intensive Care Unit, Conventionnal
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

        - All consecutive patients with COVID-19 infection admitted to the ICU or hospitalized
        because of severe form (eg: hypoxia, orthopnea, pneumonitis, kidney insufficiency) will be
        included

        Exclusion Criteria:

        - Patients under 18 years
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>Denis DOYEN</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHU de NICE - Archet 1</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Denis DOYEN</last_name>
    <phone>0033492035510</phone>
    <email>doyen.d@chu-nice.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Centre Hospitalier de Cannes</name>
      <address>
        <city>Cannes</city>
        <zip>06400</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pierre-Marie BERTRAND</last_name>
      <email>PM.BERTRAND@ch-cannes.fr</email>
    </contact>
    <contact_backup>
      <last_name>Alexandre ROBERT</last_name>
      <email>A.ROBERT@ch-cannes.fr</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier de Draguignan</name>
      <address>
        <city>Draguignan</city>
        <zip>83300</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andres Jurado</last_name>
      <email>andres.jurado@wanadoo.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier de Grasse</name>
      <address>
        <city>Grasse</city>
        <zip>06130</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pierre-Marie Bertrand</last_name>
      <email>pm.bertrand@ch-cannes.fr</email>
    </contact>
    <contact_backup>
      <last_name>Alexandre Robert</last_name>
      <email>a.robert@ch-cannes.fr</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>CHU de Nice</name>
      <address>
        <city>Nice</city>
        <zip>06200</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Denis DOYEN</last_name>
      <phone>0033492035510,</phone>
      <email>doyen.d@chu-nice.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hôpitaux Universitaires Paris Centre - Hôpital Cochin</name>
      <address>
        <city>Paris</city>
        <zip>75014</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mathieu Jozwiak</last_name>
      <phone>0033158412661</phone>
      <email>mathieu.jozwiak@aphp.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>April 3, 2020</study_first_submitted>
  <study_first_submitted_qc>April 3, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 6, 2020</study_first_posted>
  <last_update_submitted>May 12, 2020</last_update_submitted>
  <last_update_submitted_qc>May 12, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 13, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pulmonary Embolism</mesh_term>
    <mesh_term>Myocardial Infarction</mesh_term>
    <mesh_term>Thrombosis</mesh_term>
    <mesh_term>Acute Coronary Syndrome</mesh_term>
    <mesh_term>Thromboembolism</mesh_term>
    <mesh_term>Embolism</mesh_term>
    <mesh_term>Venous Thromboembolism</mesh_term>
    <mesh_term>Venous Thrombosis</mesh_term>
    <mesh_term>Myocarditis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>no data sharing plan has been established.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

